Sergio Thal is a Cardiology physician. OpenAlex indexes 55 publications with 647 citations (h-index 12); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
3601 S 6th Ave
Tucson, AZ 857230001
Telephone
520-792-1450Registry record last updated 8 Jul 2007.
Clinical trials
- POsition of Leads in Advanced heaRt Failure: the POLAR Study
Sponsor: Sergio Thal, M.D.
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
19 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Abbott LaboratoriesProgram year20257 payments
- Biosense Webster, Inc.Program year20253 payments
- Medtronic, Inc.Program year20252 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
71.1%Antiarrhythmic44.3%Amiodarone Hcl54%Flecainide Acetate41%Dofetilide5%Part D≥67 patientsBeta blocker24.8%Metoprolol Succinate76%Metoprolol Tartrate19%Sotalol5%Part D<11 patients+ 1 more class in this area
Blood & clotting
28.9%Factor Xa inhibitor28.9%Eliquis71%Xarelto29%Part D≥50 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Estrategia invasiva versus conservadora en la angina inestable de alto riesgo
Revista Argentina de Cardiología
2026 - Aspectos socioeconómicos en la utilización de recursos en pacientes con síndromes coronarios agudos. CONAREC VII
Revista Argentina de Cardiología
2026 - Outcomes after ventricular tachycardia ablation in patients with left ventricular assist device: a retrospective multicenter cohort study
Journal of Interventional Cardiac Electrophysiology
2026 - Umbral de desfibrilación elevado: ¿los vectores de desfibrilación son importantes?
Revista Argentina de Cardiología
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Gregory Y.H. Lip
Medical University of Białystok
Mika Kivimäki
University of Helsinki
Salim Yusuf
Population Health Research Institute
Victoria Delgado
Institute of Molecular Bioimaging and Physiology
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”